ArticleCancer immunology, immunotherapy : CII2007
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.
Article in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.Nature medicine · 2026Article
- Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy.Molecular medicine (Cambridge, Mass.) · 2025Review
- Adoptive T Cell Therapy Targeting MAGE-A4.Cancers · 2025Review
- Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.Oncoimmunology · 2020Article
- Expression of Cancer Testis Antigens in Colorectal Cancer: New Prognostic and Therapeutic Implications.Disease markers · 2016Article
- Targeting cancer testis antigens for biomarkers and immunotherapy in colorectal cancer: Current status and challenges.World journal of gastrointestinal oncology · 2015Review
- A Panel of Cancer Testis Antigens and Clinical Risk Factors to Predict Metastasis in Colorectal Cancer.Journal of biomarkers · 2014Article
- Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.PloS one · 2013Article
- Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters.International journal of clinical and experimental pathology · 2013Article
- TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Clinical & developmental immunology · 2012Article
- MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer.British journal of cancer · 2008Article
- Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.Journal of the National Cancer Institute · 2008Article
- Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer.Cancer immunity · 2008Article
- Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients.International journal of colorectal disease · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-specific gene products, such as cancer/testis (CT) antigens, constitute promising targets for the development of T cell vaccines. Whereas CT antigens are frequently expressed in melanoma, their expression in colorectal cancers (CRC) remains poorly characterized. Here, we have studied the expression of the CT antigens MAGE-A3, MAGE-A4, MAGE-A10, NY-ESO-1 and SSX2 in CRC because of the presence of well-described HLA-A2-restricted epitopes in their sequences. Our analyses of 41 primary CRC and 14 metastatic liver lesions confirmed the low frequency of expression of these CT antigens. No increased expression frequencies were observed in metastatic tumors compared to primary tumors. Histological analyses of CRC samples revealed heterogeneous expression of individual CT antigens. Finally, evidence of a naturally acquired CT antigen-specific CD8(+) T cell response could be demonstrated. These results show that the expression of CT antigens in a subset of CRC patients induces readily detectable T cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.